COMPANY RESEARCHKeymed Biosciences, Inc.
Keymed Biosciences is a Hong Kong-listed biopharmaceutical company focused on discovering and developing novel therapeutic antibodies. Its research includes antibodies, multispecific formats and antibody-drug conjugates, with a focus on immune-mediated diseases, chronic conditions and cancers. The company has capabilities extending from early discovery through clinical development and works toward manufacturing and commercialization of selected treatments. Its website provides corporate information and descriptions of key technology platforms. Antibody engineering and immune disease research remain central to its scientific positioning.
Company at a glance
Corporate information
- Company entity
- Keymed Biosciences, Inc.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.keymedbio.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
HKEX: 02162
antibody therapeutics · bispecific antibodies · antibody-drug conjugates
autoimmune disease · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Keymed Biosciences is a Hong Kong-listed biopharmaceutical company focused on discovering and developing novel therapeutic antibodies. Its research includes antibodies, multispecific formats and antibody-drug conjugates, with a focus on immune-mediated diseases, chronic conditions and cancers. The company has capabilities extending from early discovery through clinical development and works toward manufacturing and commercialization of selected treatments. Its website provides corporate information and descriptions of key technology platforms. Antibody engineering and immune disease research remain central to its scientific positioning.
Business, technology & evidence
- SecuritiesHKEX: 02162
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Keymed Biosciences, Inc. ↗Keymed Biosciences, Inc. ·
- Official issuer and R&D disclosure · Keymed Biosciences, Inc. ↗Keymed Biosciences, Inc. ·
- Official issuer and R&D disclosure · Keymed Biosciences, Inc. ↗Keymed Biosciences, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.